Directors

Gerald E. Bisbee, Jr., Ph.D
Chairman, President and CEO
ReGen Biologics, Inc.

Gerald Bisbee joined ReGen in 1998. Prior to ReGen, Dr. Bisbee was chairman and CEO of APACHE Medical Systems, Inc., a company providing clinical trial and FDA advisory services to device and pharmaceutical companies, and offering an industry-leading information management system for high-cost, high-risk patients. Following sale of the assets of APACHE, Dr. Bisbee became the Chairman of its successor corporation, AROS Corporation, which entered into a reverse merged transaction with ReGen to form ReGen Biologics, Inc.  Prior to APACHE, Dr. Bisbee was Chairman and CEO of Sequel Corporation, an orthopaedic rehabilitation practice management and manufacturing company that became part of the Hanger Orthopedic Group. Dr. Bisbee holds a Ph.D. from Yale University in chronic disease epidemiology with an emphasis in musculo-skeletal disease. His dissertation is part of the development of DRGs. Dr. Bisbee is a co-author of the first national orthopaedic study entitled, Musculoskeletal Disorders: Their Frequency of Occurrence and Their Impact on the Population of the United States. He holds an M.B.A. from University of Pennsylvania’s Wharton School and a B.A. from North Central College.  Dr. Bisbee is also a director of Cerner Corporation and Care Investment Trust.

Abhi Acharya, Ph.D.
Director since 2003

Dr. Acharya served at the Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration (FDA) from 1977 to 1993 holding a variety of positions including Director, Division of Cardiovascular, Respiratory and Neurological Devices, and Chief of Surgical Devices Branch.  Most recently, Dr. Acharya served as Senior Vice President, Regulatory Affairs, Quality, Clinical Research of EndoTex Interventional Systems, Vice President, Regulatory Affairs, Quality Assurance and Clinical Research of Target Therapeutics, Inc. and Senior Technical Advisor at Biometric Research Institute, Inc. Dr. Acharya has authored numerous publications, and he has received the FDA Award of Merit, the Commendable Service Award, and the Commissioner's Special Citation. He earned his M.S. and Ph.D. in Biomedical Engineering from Northwestern University and a B.S. in Metallurgical Engineering from the Indian Institute of Technology.  Dr. Acharya serves on the board of directors of Neomend, Inc., Stereotaxis, Inc. and InfraReDx, Inc.


Alan W. Baldwin
Director since 2000
Chairman of Audit Committee

Mr. Baldwin was most recently President and Chief Operating Officer of Argosy Chemical International. He was previously president of Alcore, a division of the McGill Corporation. Prior to joining Alcore, Mr. Baldwin was the Chief Executive Officer of CopperGlass Optical Solutions, Inc.; and director of Wren Associates, Ltd.  Mr. Baldwin is a graduate of the U.S. Military Academy at West Point, New York and received his Masters Degree in engineering and mathematics from the University of Alabama.


Robert G. McNeil, Ph.D.
General Partner, Sanderling Ventures
Director since 2002

Dr. McNeil has over twenty-five years experience as an active investor and management participant in seed and early-stage biomedical companies. Dr. McNeil has served as a director of ReGen from 1990 to 2002. He founded Sanderling Ventures in 1979 and has served since then as the general partner of Sanderling's investment partnerships. Dr. McNeil was a seed-stage investor in Advanced Cardiovascular Systems, Inc. and Venitrex, Inc., two privately-held medical device companies. He was a founder, Chief Executive Officer and Chairman of CoCensys, the Chief Executive Officer and Chairman of Acea, and the Chairman of Peregrine Pharmaceuticals, a publicly-held company. Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics from the University of California, Irvine. Following his graduation, he pursued a long-time interest in investing by joining Shuman Agnew & Co., a San Francisco investment firm, where he worked as a portfolio manager and investment analyst.  Dr. McNeil is Chairman of the Board of InfraReDx, Inc.


J. Richard Steadman, M.D.
Founder and Partner, Steadman Hawkins Clinic
Director since 2002

Dr. Steadman conducts an orthopedic surgery practice at the Steadman Hawkins Clinic in Vail, Colorado, and is globally recognized for his expertise in sports medicine, surgery and rehabilitation. Dr. Steadman has served as a director of ReGen from 1990to 2002. Dr. Steadman has received numerous national and international awards including the Albert Trillat Award for Excellence in Knee Research from the International Society for the Knee, the H. Edward Cabaud Memorial Award for Knee Research from the American Orthopaedic Society for Sports Medicine, and the highly prestigious GOTS-Beiersdorf (Germany) Prize. He is also a member of the U.S. Ski Hall of Fame. Dr. Steadman holds a BS in Biology (pre-med) from Texas A&M and an M.D. from the University of Texas, Southwestern Medical School. He completed his Orthopedic Surgery Residency at Charity Hospital (LSU) in New Orleans.


William R. Timken
Founding Partner, Hambrecht & Quist
Director since 2004

Mr. Timken joined ReGen in June 2004 and also serves as a member of the Audit Committee of the board of directors.  A founding partner of Hambrecht & Quist, Timken joined H&Q in 1968 and retired in 1999 as its Vice Chairman.  During his forty-two year career as a securities industry executive, he has been involved in bringing to market and capitalizing companies such as Genentech, Apple and Netscape.  He has been an active healthcare investor with a focus on medical technology and biotech and has been a valued investor and advisor to ReGen Biologics since 1992.  He is a graduate of Colby College, and has served on the Blair Academy Board of Trustees since 1981, where he was elected Chairman in 2001.